Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Ross, Christopher A ^a   Shoulson, Ira ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

BDNF; Coenzyme Q10; HDAC; huntingtin; MRI; PHAROS; PREDICT HD; Rhes; striatum; TRACK HD

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTISENSE OLIGONUCLEOTIDE; ARYLBUTYRIC ACID DERIVATIVE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CREATINE; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; MUTANT PROTEIN; PLACEBO; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; SMALL INTERFERING RNA; UBIDECARENONE;

ACETYLATION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENVIRONMENTAL STRESS; EXPERIMENTAL STUDY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; METABOLIC STRESS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; RNA INTERFERENCE; SUMOYLATION;

BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 72149084425     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70800-4     Document Type: Article

References (38)

1. Hendricks A.E., Latourelle J.C., Lunetta K.L., Cupples L.A., Wheeler V., Macdonald M.E., et al. Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). Am J Med Genet 149A 7 (2009 Jul) 1375-1381
2. Quaid K., Sims S., Swenson M., Harrison J., Moskowitz C., Stepanov N., et al., the Huntington Study Group PHAROS Investigators. Living at risk: Concealing risk and preserving hope in Huntington's disease. Neurotherapeutics 5 2 (2008) 368-369
3. The Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol 63 7 (2006 Jul) 991-996
4. Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E., Ross C.A., et al., the PREDICT-HD Investigators of the Huntington Study Group. Preparing for preventive clinical trials: the PREDICT-HD study. Arch Neurol 63 6 (2006 Jun) 883-890
5. Biglan K.M., Ross C.A., Langbehn D.R., Aylward E.H., Stout J.C., Queller S., et al., the PREDICT-HD Investigators of the Huntington Study Group. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 24 12 (2009 Sep 15) 1763-1772
6. Kayson E., and the Huntington Study Group PHAROS Investigators. Five years of monitoring the safety and feasibility of PHAROS (prospective Huntington at risk observational study). Neurotherapeutics 5 2 (2008) 366
7. Aylward E.H., Rosenblatt A., Field K., Yallapragada V., Kieburtz K., McDermott M., et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 62 2 (2003 Dec 15) 137-141
8. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8 9 (2009 Sep) 791-801
9. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63 1 (2004 Jul 13) 66-72
10. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 131 Pt 4 (2008 Apr) 1057-1068
11. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., and Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65 5 (2005 Sep 13) 745-747
12. Reading S.A., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 140 1 (2005 Oct 30) 55-62
13. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 46 4 (2009 Jul 15) 958-966
14. Reading S.A., Dziorny A.C., Peroutka L.A., Schreiber M., Gourley L.M., Yallapragada V., et al. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 55 6 (2004 Jun) 879-883
15. Paulsen J.S. Functional imaging in Huntington's disease. Exp Neurol 216 2 (2009 Apr) 272-277
16. Martin W.R., Wieler M., and Hanstock C.C. Is brain lactate increased in Huntington's disease?. J Neurol Sci 263 1-2 (2007 Dec 15) 70-74
17. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler Jr. J.F., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5 10 (1999 Oct) 1194-1198
18. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66 2 (2006 Jan 24) 250-252
19. Hardy J., Cai H., Cookson M.R., Gwinn-Hardy K., and Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60 4 (2006 Oct) 389-398
20. Ross C.A., and Smith W.W. Gene-environment interactions in Parkinson's disease. Parkinsonism Relat Disord 13 Suppl 3 (2007) S309-S315
21. Schwarcz R., Guidetti P., Sathyasaikumar K.V., and Muchowski P.J. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009 Apr 24)
22. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205 8 (2008 Aug 4) 1869-1877
23. Brouillet E., Conde F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59 5 (1999 Dec) 427-468
24. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14 19 (2005 Oct 1) 2871-2880
25. Tobin A.J., and Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol 10 12 (2000 Dec) 531-536
26. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412 2 (2008 Jun 1) 191-209
27. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17 6 (2009 Jun) 1053-1063
28. Pfister E.L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19 9 (2009 May 12) 774-778
29. Subramaniam S., Sixt K.M., Barrow R., and Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324 5932 (2009 Jun 5) 1327-1330
30. Gusella J.F., and Macdonald M.E. Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci 31 9 (2006 Sep) 533-540
31. Giaime E., Sunyach C., Druon C., Scarzello S., Robert G., Grosso S., et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differentiation (2009 Aug 14)
32. Kazantsev A.G., and Hersch S.M. Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 83 4 (2007 Nov) 249-259
33. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100 4 (2003 Feb 18) 2041-2046
34. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 6857 (2001 Oct 18) 739-743
35. Duan W., Guo Z., Jiang H., Ladenheim B., Xu X., Cadet J.L., et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55 4 (2004 Apr) 590-594
36. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30 3 (2008 Jun) 312-322
37. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci USA 106 12 (2009 Mar 24) 4906-4911
38. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 3 (2001 Aug 14) 397-404